Novacea Announces Resignation of Two Board Members
"The transition in the constituency of our board of directors is part of the natural evolution of a publicly-traded biotechnology company. Concurrent with this, we will be reducing the size of our board of directors from nine to seven, which is more consistent with industry standards and Novacea's stage of development. Jim Blair's and Jay Moorin's leadership and service over the past six years have made a significant impact on the growth and direction of our company. We wish them both every success in their future endeavors," said John P. Walker, chairman and interim chief executive officer of Novacea.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.